EULAR

EULAR 2024 - Collaboration and innovation to transform rheumatology

Vandenbruaene Nathalie — Mon, 10 Jun 2024 11:21:33 +0000

EULAR 2024 - Collaboration and innovation to transform rheumatology

John Ioannou, Medical Affairs Rheumatology

Vandenbruaene … Mon 10/06/2024 - 13:21

The burden of chronic rheumatic diseases (CRD) worldwide is huge. For example, around 18 million people worldwide live with rheumatoid arthritis (RA) and it’s estimated that one person in every 150 is affected by axial spondyloarthritis (axSpA). CRDs like RA, axSpA and psoriatic arthritis (PsA) can have a severe impact on quality of life: relapsing and remitting in nature, the pain and loss in mobility associated with certain CRDs can make basic day-to-day-tasks a challenge. While we’ve made progress in the management of CRDs, we are more aware than ever of the significant unmet needs which remain and the work left for us to achieve our ambition of doubling the rate of remission and halving the rate of disease progression across all CRDs by 2030.

That’s why chances to connect and share knowledge with the rheumatology community are so important and why I’m particularly proud of ��ֳ�’s presence at the European Congress of Rheumatology, EULAR 2024. It’s inspiring to see the different ways we’re collectively advancing the standard of care, approaching problems from various angles but with the personal needs of the patient always at the center.

With 18 abstracts accepted at EULAR this year, the breadth and depth of our scientific contribution highlight our commitment to achieving our 2030 ambition in rheumatology. We’re at the cutting edge of advancing personalized medicine, and I’m excited for our symposia which will help show the European rheumatology community how our increased understanding of the immunological mechanisms underlying various CRDs can help people achieve better control over their conditions.

In addition, I’m proud of our ability to deliver more and better-quality data on CRDs in underserved populations, particularly women of childbearing age. Women living with CRDs, along with their healthcare professionals, can often lack sufficient data and information about disease management, treatment options, and family planning. Our commitment to research in this area directly empowers women and their care providers to make informed decisions.

We wholeheartedly support ��ֳ�’s aspiration to push the standard of care in rheumatology, to move from symptomatic treatment towards long-lasting, drug-free remission, with the ultimate aim of achieving a cure for CRDs. Looking at the great research being shared at EULAR, that goal is feeling closer than ever.

If you’re joining us in Vienna, be sure to swing by and say hi to the team – see you there!

about ucb

272 Likes

Patients, partnerships and innovation – Exploring the future of rheumatology at EULAR 2023

Vanco Vlastimil (��ֳ� S.A.) — Thu, 01 Jun 2023 09:11:10 +0000

Patients, partnerships and innovation – Exploring the future of rheumatology at EULAR 2023

Athanasia Gkiouleka, Rheumatology Mission

Vanco Vlastimi… Thu 01/06/2023 - 11:11

The future of rheumatology presents a level of optimism we have not seen before, with innovation and science consistently improving the lives of people living with rheumatic diseases. This is clear to see at EULAR – the annual congress held by the European Alliance of Associations for Rheumatology – held this month in Milan, Italy.

EULAR brings together experts from across the world to discuss the latest and greatest ground-breaking research in rheumatology across multiple diseases – many of which have remaining high unmet needs requiring effective solutions.

I’m excited to be part of the discussion in rheumatology alongside experts in the field. Here at ��ֳ�, we welcome the opportunity to transform the lives of people living with both immune-mediated inflammatory diseases and osteoporosis. At this year’s EULAR, we are presenting 23 abstracts that highlight not only our expanding rheumatology portfolio but also our enduring effort to advance care for diverse immune-mediated inflammatory conditions.

Our approach to supporting people living with chronic rheumatic diseases is centered on three things:

Patients – we deeply care about patients and want to understand their perspective, and so we listen and observe what they’re doing, what they need, what they want and what they hope for.
Partnerships – we partner with the medical community, patient organizations, payers and other stakeholders to offer the most appropriate solutions to improve patients’ lives.
Innovation – we are bold, not only in our science, our research, and our development, but we are also bold in how we connect to our patients’ world to deliver for them.

This approach underpins our entire rheumatology strategy and through our research, we push ourselves to address the prominent unmet needs of three key groups of people living with rheumatic diseases – our core populations for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), those living with systemic lupus erythematosus (SLE) and osteoporosis, and lastly, new populations of remaining high unmet need such as in fibromyalgia. We’re delighted to present new data across two of these areas at EULAR – our core populations of PsA and axSpA, and SLE.

Enhancing quality of life in PsA and axSpA

The evolution of our rheumatology portfolio enables us to deliver and expand value for people living with axSpA and PsA, to support a better quality of life. At EULAR we are excited to present data in active PsA. In addition to this, we are also presenting results from studies which explore potential new solutions to treat the full spectrum of axSpA (encompassing non-radiographic axSpA and ankylosing spondylitis).i,ii We’re hopeful that these results will take us a step closer to improving the lives of people living with PsA and axSpA.

Our innovative pipeline

Our pipeline is focused on driving scientific advancements in chronic autoimmune diseases where there is an extremely high unmet need and great potential to provide long-term value for patients. We are determined to help ease the burden of people suffering from diseases like SLE and provide them with new options.

The future

We are lucky to live in an era that allows us to deepen our understanding of rheumatic diseases and explore innovative and novel ways to support patients. We are committed to continuing our work with patients, organizations, and the medical community to reduce the time to diagnosis and support quicker access to biologic therapies alongside our innovative portfolio of products in order to build our offering and further help people live better lives.

For me, what I ultimately hope is that we will not stop until we find solutions for all patients, and I’m excited for what the future holds and the possibilities we will be able to explore.

about ucb

EULAR Rheumatology Patients Partnerships Innovation axSpA PsA SLE

375 Likes

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Vandenbruaene Nathalie — Wed, 01 Jun 2022 08:56:30 +0000

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

John Ioannou, Medical Affairs, Rheumatology

Vandenbruaene … Wed 01/06/2022 - 10:56

As an organisation, we always feel a great sense of pride when ��ֳ� takes part in the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, and this year feels extra special. EULAR is celebrating an impressive milestone – its 75th anniversary – and the congress is being held as a hybrid congress for the very first time.

Thousands of delegates from across the world will be coming together both virtually and on-site in Copenhagen, Denmark. The opportunity to connect virtually for the last two years has been invaluable, however, being able to meet with some of our friends and colleagues in person for scientific exchange is something I am sure we are all looking forward to.

At this year’s congress, ��ֳ� will be sharing a wealth of new and important clinical data. In particular, we are proud to be sharing the first presentations of our pivotal Phase 3 data from our extensive research programmes in psoriatic arthritis and axial spondyloarthritis. The depth of our research programmes is testimony to our continuing commitment to delivering real value for people living with these conditions.

In addition, our three sponsored scientific symposia will bring the rheumatology community together to discuss and debate ‘Raising the Target for Patients Living with Psoriatic Arthritis’, ‘Raising the Target for Patients Living with Axial Spondyloarthritis’ and ‘Evolving Concepts in axSpA-2022 Update’. To enhance scientific exchange, we are also pleased to support a ‘Consult the Expert’ session focused on enthesitis management. We look forward to continuing discussions around the latest advancements in the rheumatology field at our exhibition booth, where members of our ��ֳ� team will be ready and pleased to welcome all those in attendance.

We are honoured to be partnering with our esteemed colleagues and peers to drive the future of rheumatology at this year’s congress. We look forward to being a part of EULAR 2022!

You can stay up to date on the latest ��ֳ� news at EULAR 2022 through our social media channels (Twitter, LinkedIn).

about ucb

EULAR Rheumatology psoriatic arthritis axial spondyloarthritis

473 Likes

EULAR

EULAR 2024 - Collaboration and innovation to transform rheumatology

Leave a Comment

Patients, partnerships and innovation – Exploring the future of rheumatology at EULAR 2023

Leave a Comment

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Leave a Comment

EULAR

EULAR 2024 - Collaboration and innovation to transform rheumatology

Leave a Comment

Patients, partnerships and innovation – Exploring the future of rheumatology at EULAR 2023

Leave a Comment

EULAR 2022: ������ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology

Leave a Comment

EULAR 2022: ��ֳ� unites with the community to share the latest scientific breakthroughs and clinical research in rheumatology